Notification of cessation of securities - TLX

Notification regarding unquoted securities - TLX

Application for quotation of securities - TLX

Change in substantial holding

Ceasing to be a substantial holder

FDA Alignment to Advance ProstACT Global Phase 3 Trial

Change in substantial holding

Change in substantial holding

Becoming a substantial holder

Becoming a substantial holder

Ceasing to be a substantial holder

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help

Appendix 3Y Change in Director Interest D Gill

Change in substantial holding

Telix and United Imaging Announce Strategic Theranostics Collaboration

Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms. Initial focus on TLX101-Px (Pixclara® 1, Floretyrosine F 18) in the U.S. Framework to support potential co-development, validation, and deployment

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026

Telix’s first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safety signals. Findings support feasibility of TLX591-Tx in combination with contemporary SoC in

Notification regarding unquoted securities - TLX

Appendix 3Y Change in Director Interest - C Behrenbruch

Appendix 3Y Change in Director Interest - M McDonald

Appendix 3Y Change in Director Interest - W Jellison

Appendix 3Y Change in Director Interest - Maria Rivas

Appendix 3Y Change in Director Interest - David Gill

Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences

MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46 th Annual Growth Stock Conference in

Becoming a substantial holder

Results of Annual General Meeting

Telix Annual General Meeting Presentation

Telix Annual General Meeting Chairman and CEO Addresses

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. Maximum dose reached with no dose-limiting toxicities observed. TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma.

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.

App 3X Initial Director Interests - W Jellison

App 3X Initial Director Interests - M Rivas

App 3X Initial Director Interests - D Gill

Change in substantial holding

Cleansing Notice

Application for quotation of securities - TLX

Notification regarding unquoted securities - TLX

Ceasing to be a substantial holder from CGF

New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

MELBOURNE, Australia and INDIANAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology 1, demonstrating that TLX250-Px (Zircaix® 2, 89

TLX101-Px (Pixlumi®) MAA Accepted in Europe

MELBOURNE, Australia and INDIANAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[ 18 F]fluoroethyl)-L-tyrosine, 18 F-FET), its glioma (brain

Appendix 3Y Change in Director Interests - C Behrenbruch

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

TLX597-Tx is a PSMA 1 -targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer. OPTIMAL-PSMA 2 initial dosimetry data demonstrate low salivary gland and kidney uptake, supporting dose intensification.

Pending Release of Shares from Voluntary Escrow

Change in substantial holding

Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces an educational webinar exploring the evolution of PSMA [1] -targeted radionuclide therapy and Telix's differentiated, multi-product approach to treating

Webinar - A Next-Gen Portfolio Approach to PSMA Therapy

Notification regarding unquoted securities - TLX

Telix Announces Settlement of US$600M Convertible Bonds

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the ProstACT Global Phase 3 study (Part 1) will be presented as a late-breaking oral presentation at the

Telix Notice of AGM, Proxy Form and Online Guide

Convertible Bond Cleansing Notice

Becoming a substantial holder from CGF

Change in substantial holding